Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Role of the PI3K Pathway in the Pathogenesis of Marginal Zone Lymphoma

Ariel Sindel, DO, Ian McConnell, MS, Jolene Windle, PhD, Roy Sabo, PhD, Alden Chesney, MD, Guanhua Lai, MD PhD, Adolfo Mauro, PhD, Taha Al-Juhaishi, MD, Mohamed Rahmani, PhD, Jamal Zweit, PhD, Steven Grant, MD, Steven Grossman, MD, Victor Youssef Yazbeck, MD

Blood (2018) 132 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2018-99-111284

Published: 2018

Journal Articles

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Tianyu Cai, PhD, Philip L Lorenzi, PhD, Dinesh Rakheja, MD, Michael A Pontikos, Alessia Lodi, Lina Han, MD PhD, Qi Zhang, MD PhD, Helen Ma, MS, Mohamed Rahmani, PhD, Tushar Damodar Bhagat, PhD, Thomas D Horvath, PhD, Courtney D. DiNardo, MD MSCE, Steven Grant, MD, Stefano Tiziani, PhD, Amit Verma, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4064.

https://doi.org/10.1182/blood.V128.22.4064.4064

Published: 2016

Journal Articles

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

Liang Zhou, Shuang Chen, Yu Zhang, Maciej Kmieciak, Yun Leng, Lihong Li, Hui Lin, Kathryn A. Rizzo, Catherine I. Dumur, Andrea Ferreira-Gonzalez, Mohamed Rahmani, Lawrence Povirk, Sri Chalasani, Allison J. Berger, Yun Dai, Steven Grant

Blood (2016) 127 (18): 2219–2230.

https://doi.org/10.1182/blood-2015-06-653717

Published: 2016

Includes: Supplemental data

Journal Articles

Co-Administration of the mTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-Xl Antagonist ABT-737 Kills Human Myeloid Leukemia Cells through Mcl-1 Down-Regulation and AKT Inactivation

Mohamed Rahmani, PhD, Mandy Mayo Aust, Elisa Hawkins, Rebecca E Parker, Leonid Reshko, Masey Ross, MD, Maciej Kmieciak, PhD, Kathryn Ann Rizzo, DO, PhD, Catherine I Dumur, PhD, Andrea Ferreira-Gonzalez, PhD, Steven Grant, MD

Blood (2015) 126 (23): 3676.

https://doi.org/10.1182/blood.V126.23.3676.3676

Published: 2015

Journal Articles

Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation

Justin Sperlazza, Mohamed Rahmani, Jason Beckta, Mandy Aust, Elisa Hawkins, Shou Zhen Wang, Sheng Zu Zhu, Shreya Podder, Catherine Dumur, Kellie Archer, Steven Grant, Gordon D. Ginder

Blood (2015) 126 (12): 1462–1472.

https://doi.org/10.1182/blood-2015-03-631606

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms

Mohamed Rahmani, Ph.D, Mandy Aust, MS, LaShanale Wallace, BS, Steven Grant, MD

Blood (2013) 122 (21): 817.

https://doi.org/10.1182/blood.V122.21.817.817

Published: 2013

Journal Articles

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process

Mohamed Rahmani, Mandy Mayo Aust, Elisa Attkisson, David C. Williams, Jr, Andrea Ferreira-Gonzalez, Steven Grant

Blood (2012) 119 (25): 6089–6098.

https://doi.org/10.1182/blood-2011-09-378141

Published: 2012

Includes: Supplemental data

Journal Articles

The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways

Mohamed Rahmani, Anh Anderson, Joseph Reza Habibi, Timothy Ryan Crabtree, Mandy Mayo, Hisashi Harada, Andrea Ferreira-Gonzalez, Paul Dent, Steven Grant

Blood (2009) 114 (20): 4507–4516.

https://doi.org/10.1182/blood-2008-09-177881

Published: 2009

Includes: Supplemental data

Journal Articles

A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia

Steven W. Paugh, Barbara S. Paugh, Mohamed Rahmani, Dmitri Kapitonov, Jorge A. Almenara, Tomasz Kordula, Sheldon Milstien, Jeffrey K. Adams, Robert E. Zipkin, Steven Grant, Sarah Spiegel

Blood (2008) 112 (4): 1382–1391.

https://doi.org/10.1182/blood-2008-02-138958

Published: 2008

Journal Articles

MEK1/2 inhibitors sensitize Bcr/Abl + human leukemia cells to the dual Abl/Src inhibitor BMS-354/825

Tri K. Nguyen, Mohamed Rahmani, Hisashi Harada, Paul Dent, Steven Grant

Blood (2007) 109 (9): 4006–4015.

https://doi.org/10.1182/blood-2006-09-045039

Published: 2007

Journal Articles

The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism

Girija Dasmahapatra, Mohamed Rahmani, Paul Dent, Steven Grant

Blood (2006) 107 (1): 232–240.

https://doi.org/10.1182/blood-2005-06-2302

Published: 2006

Journal Articles

Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress

Ning Gao, Mohamed Rahmani, Xianglin Shi, Paul Dent, Steven Grant

Blood (2006) 107 (1): 241–249.

https://doi.org/10.1182/blood-2005-06-2409

Published: 2006

Journal Articles

Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK

Yun Dai, Mohamed Rahmani, Xin-Yan Pei, Payal Khanna, Song Iy Han, Clint Mitchell, Paul Dent, Steven Grant

Blood (2005) 105 (4): 1706–1716.

https://doi.org/10.1182/blood-2004-07-2767

Published: 2005

Journal Articles

Highly Synergistic Interaction between Farnesyltransferase Inhibitors and the Chk1 Inhibitor UCN-01 to Induce Apoptosis in Human Leukemia Cells through Interruption of Both Akt and MEK/ERK Pathways and Activation of SEK1/JNK.

Yun Dai, Ph.D., Mohamed Rahmani, Ph.D., Xin-Yan Pei, M.D., Payal Khanna, Paul Dent, Ph.D., Steven Grant, M.D.

Blood (2004) 104 (11): 3403.

https://doi.org/10.1182/blood.V104.11.3403.3403

Published: 2004

Journal Articles

Co-Administration of SAHA and 17-AAG Synergistically Induces Apoptosis in Bcr-Abl + Cells Sensitive and Resistant to STI-571 in Association with Down-Regulation of Bcr-Abl, Abrogation of STAT5 Activity, and Bax Conformational Change.

Mohamed Rahmani, Erin Reese, Yun Dai, Cheryl Bauer, Lora Kramer, Mei Huang, Richard Jove, Paul Dent, Steven Grant

Blood (2004) 104 (11): 1995.

https://doi.org/10.1182/blood.V104.11.1995.1995

Published: 2004

Journal Articles

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

Yun Dai, Mohamed Rahmani, Xin-Yan Pei, Paul Dent, Steven Grant

Blood (2004) 104 (2): 509–518.

https://doi.org/10.1182/blood-2003-12-4121

Published: 2004

Journal Articles

Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells

Yun Dai, Xin-Yan Pei, Mohamed Rahmani, Daniel H. Conrad, Paul Dent, Steven Grant

Blood (2004) 103 (7): 2761–2770.

https://doi.org/10.1182/blood-2003-09-3037

Published: 2004

Journal Articles

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl + cells sensitive and resistant to STI571

Chunrong Yu, Mohamed Rahmani, Daniel Conrad, Mark Subler, Paul Dent, Steven Grant

Blood (2003) 102 (10): 3765–3774.

https://doi.org/10.1182/blood-2003-03-0737

Published: 2003

Journal Articles

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways

Wentao Jia, Chunrong Yu, Mohamed Rahmani, Geoffrey Krystal, Edward A. Sausville, Paul Dent, Steven Grant

Blood (2003) 102 (5): 1824–1832.

https://doi.org/10.1182/blood-2002-12-3785

Published: 2003

NARROW

Role of the PI3K Pathway in the Pathogenesis of Marginal Zone Lymphoma

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

Co-Administration of the mTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-Xl Antagonist ABT-737 Kills Human Myeloid Leukemia Cells through Mcl-1 Down-Regulation and AKT Inactivation

Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation

Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process

The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways

A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia

MEK1/2 inhibitors sensitize Bcr/Abl + human leukemia cells to the dual Abl/Src inhibitor BMS-354/825

The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism

Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress

Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK

Highly Synergistic Interaction between Farnesyltransferase Inhibitors and the Chk1 Inhibitor UCN-01 to Induce Apoptosis in Human Leukemia Cells through Interruption of Both Akt and MEK/ERK Pathways and Activation of SEK1/JNK.

Co-Administration of SAHA and 17-AAG Synergistically Induces Apoptosis in Bcr-Abl + Cells Sensitive and Resistant to STI-571 in Association with Down-Regulation of Bcr-Abl, Abrogation of STAT5 Activity, and Bax Conformational Change.

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl + cells sensitive and resistant to STI571

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only